Oseltamivir 30mg caps/PAC-10
Oseltamivir 30mg capsules, pack of 10
Indicative Price : 7.76 USD
Oseltamivir 30mg capsules pack of 10.
Oseltamivir is active against influenza A and B viral neuraminidase. Its active metabolite, oseltamivir carboxylate, selectively blocks the viral surface enzyme neuraminidase, thereby preventing the release of virus particles from infected cells.
The most commonly reported adverse effects associated with oseltamivir treatment or prophylaxis in adults are nausea and vomiting, abdominal pain, bronchitis, insomnia and vertigo. Diarrhoea, dizziness, headache, cough, and fatigue may occur, but many adverse effects may be difficult to distinguish from the symptoms of influenza. Other adverse effects occurring less commonly have included unstable angina, anaemia, pseudomembranous colitis, pneumonia, pyrexia, and peritonsillar abscess.There have been occasional reports of anaphylaxis and skin rashes, including toxis epidermal necrolysis, Stevens Johnson syndrome, and erythema multiforme. Elevated liver enzymes and hepatitis have been reported rarely.
Prophylaxis in adults has also been associated with aches and pains, dyspepsia, rhinorrhea, and upper respiratory tract infections.
The most commonly reported adverse effects in children receiving treatment or prophylaxis with oseltamivir are vomiting and other gastrointestinal problems. Other commonly occurring adverse events include asthma, bronchitis, conjunctivitis, dermatitis, epistaxis, ear disorders and otitis media, lymphadenopathy, pneumonia and sinusitis.
Oseltamivir is not recommended in patients with severe renal impairment, and it should be given with caution, and dosage should be reduced in patients with moderate renal impairment. Patients should be monitored for abnormal behaviour throughout the treatment period.
Guidelines for use and administration:
Oseltamivir is a product of oseltamivir carboxylate, an inhibitor of the enzyme neuraminidase (sialidase), which has a role in the infectivity and replication of influenza A and B viruses. It is used in adults and children over 1 year of age for the treatment and postexposure prophylaxis of influenza A and B.
Oseltamivir is given orally as the phosphate, but doses are expressed in terms of the base. Oseltamivir phosphate 98.5mg is equivalent to about 75mg of oseltamivir. For the treatment of adults a dose of 75mg is given twice daily for 5 days, beginning as soon as possible (within 48 hours)after the onset of symptoms. For post exposure prophylaxis the usual dose is 75mg given once daily for at least 10 days and up to 6 weeks during an epidemic; therapy should begin within 48 hours of exposure.
Administration in children:
Oseltamivir is given orally in the treatment and prophylaxis of influenza A and B in children aged 1 year and over. Doses determined by body weight may be given twice daily for treatment, or once daily for prophylaxis, of influenza A and B as follows:
·Children over 40kg: 75mg
·More than 23kg to 40kg: 60mg
·More than 15kg to 23kg: 45mg
·15kg or less: 30mg
|To see icon descriptions, go to
' Product attribute guide'